ascopubs.org

Final analysis of SCORES, a phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer.

HER2 and HER3 expression in ovarian cancer: Evolution across chemotherapy exposure and implications for targeted therapies. Median PFS by BIRC, month (95% CI) 5.49 (4.93,6.64) 2.73 (1.94,3.75) Median ...
Cancer Therapy Advisor

KEYNOTE-522 Final Analysis: Perioperative Pembro Extends OS in High-Risk TNBC

Perioperative pembrolizumab can improve OS when combined with neoadjuvant chemotherapy in patients with high risk, ...
ascopubs.org

Final analysis of a multicenter, open-label, phase 2 study evaluating the efficacy and safety of tislelizumab (TIS) in combination with fruquintinib (F) in patients (pts) with ...

Impact of body mass index on immunotherapy outcomes and complications in solid tumor patients: A real-world evidence analysis. Median progression-free survival, mo (95% CI) 4.6 (3.4, 7.4) 4.6 (3.6, ...
The New England Journal of Medicine

Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer

In the phase 3 EMBARK trial, enzalutamide plus leuprolide and enzalutamide monotherapy were associated with longer metastasis-free survival than leuprolide alone among patients with biochemically ...
Nature

Final Analysis of a Study of Etranacogene Dezaparvovec for Hemophilia B

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
The Manila Times

Junshi Biosciences Announces Primary Endpoints Met in Final Analysis of Phase 3 Study for Perioperative Toripalimab plus Chemotherapy for Resectable Stage II-III N…

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...